BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog.

Abstract

F Hoffmann-La Roche Ltd, Teijin Ltd and Chugai Pharmaceutical Co Ltd, under license from Ipsen, are developing the glucagon-like peptide 1 analog BIM-51077, for the potential treatment of type 2 diabetes. Phase II clinical trials are underway, including a phase II trial evaluating a slow release formulation.

• Authors: Nick Giannoukakis
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 8 Issue 10 Pg. 842-8 (Oct 2007) ISSN: 1472-4472 [Print] England
• PMID: 17907061 (Publication Type: Journal Article, Review)

Chemical References

• BIM 51077
• Dipeptidyl-Peptidase IV Inhibitors
• Hypoglycemic Agents
• Glucagon-Like Peptide 1
• Dipeptidyl Peptidase 4

Topics

• Animals
• Diabetes Mellitus, Type 2 (drug therapy, enzymology)
• Dipeptidyl Peptidase 4 (metabolism)
• Dipeptidyl-Peptidase IV Inhibitors
• Drug Evaluation, Preclinical
• Glucagon-Like Peptide 1 (adverse effects, analogs & derivatives, metabolism, pharmacokinetics, therapeutic use)
• Humans
• Hypoglycemic Agents (therapeutic use)
• Structure-Activity Relationship